Takeda/Intra-Cellular Dissolve $750m+ PDE1 Partnership
This article was originally published in PharmAsia News
Executive Summary
The end of a global licensing deal with Takeda means Intra-Cellular Therapies (ITI) is regaining all rights to its lead PDE1 inhibitors for CNS and other disorders, but will lose, at least for the time being, an important source of revenue.